✦ LIBER ✦

Pharmaceutical Cost Analysis of Diabetes Mellitus Using Clinical Risk Groups in Valencian Community

✍ Scribed by Romero, M.; Uso Talamantes, R.; Vivas Consuelo, D.; De la Poza Plaza, E.; Sancho Mestre, C.; Trillo Mata, J.L.; Barrachina, I.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PHP45 Predictability of Pharmaceutical S

✍ R. Uso Talamantes; M. Caballer Tarazona; L. Buigues Pastor; J.L. Trillo Mata; N. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Predictability of pharmaceutical spendin

✍ Vivas-Consuelo, David; Usó-Talamantes, Ruth; Trillo-Mata, José Luis; Caballer-Ta 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 379 KB

Gestational Diabetes Mellitus: Clinical

✍ Lee, A. J.; Hiscock, R. J.; Wein, P.; Walker, S. P.; Permezel, M. 📂 Article 📅 2007 🏛 American Diabetes Association 🌐 English ⚖ 96 KB

Clinical and cost-effectiveness analysis

✍ Samira Humaira Habib; Salima Akter; Shahanaz Parveen; Kazal Boron Biswas; Soma S 📂 Article 📅 2008 🏛 Elsevier 🌐 English ⚖ 347 KB

Cost analysis of group versus usual care

✍ Sicuro, J.; Bondonio, P.; Charrier, L.; Berchialla, P.; Cavallo, F.; Porta, M.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Use of angiotensin-converting enzyme inh

✍ Allison B. Rosen; Andrew J. Karter; Jennifer Y. Liu; Joe V. Selby; Eric C. Schne 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB